GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO

Watchlist Manager
GlaxoSmithKline Pharmaceuticals Ltd Logo
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Watchlist
Price: 2 823.55 INR
Market Cap: 478.3B INR
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

0
Assets
+0%
Growth Rates:
1 Year
+15%
3 Years
+23%
5 Years
+6%
7 Years
-
10 Years
-
0
Liabilities
+0%
Growth Rates:
1 Year
+20%
3 Years
+18%
5 Years
+77%
7 Years
-
10 Years
-
0
Equity
+0%
Growth Rates:
1 Year
+9%
3 Years
+29%
5 Years
-29%
7 Years
-
10 Years
-

Balance Sheet Decomposition
GlaxoSmithKline Pharmaceuticals Ltd

37.5B
Assets
20.7B
Liabilities
37.5B
Assets
20.7B
Liabilities
Current Assets 30.1B
Cash & Short-Term Investments 21.9B
Receivables 2.7B
Other Current Assets 5.6B
Non-Current Assets 7.3B
Long-Term Investments 118.5m
PP&E 3B
Intangibles 183.4m
Other Non-Current Assets 4B

Balance Sheet
GlaxoSmithKline Pharmaceuticals Ltd

Rotate your device to view
Balance Sheet
Currency: INR
Millions
Ones
Thousands
Millions
Billions
Annual
Quarterly
Annual
Mar-2015 Mar-2016 Mar-2017 Mar-2018 Mar-2019 Mar-2020 Mar-2021 Mar-2022 Mar-2023 Mar-2024
Assets
Cash & Cash Equivalents
1 153
1 149
1 410
2 011
987
1 048
4 052
2 862
349
642
Cash
549
587
341
911
687
988
2 061
561
349
642
Cash Equivalents
604
562
1 069
1 100
300
60
1 991
2 301
0
0
Short-Term Investments
18 399
12 521
7 672
10 690
10 490
9 570
7 320
25 447
16 192
17 927
Total Receivables
1 424
1 817
2 395
2 415
3 288
1 907
2 975
3 052
3 419
3 720
Accounts Receivables
1 003
1 266
1 708
1 470
1 205
998
2 156
2 052
2 065
2 311
Other Receivables
421
551
687
945
2 083
909
819
1 000
1 355
1 409
Inventory
3 756
5 259
4 258
5 002
4 865
4 830
5 467
5 347
4 600
5 250
Other Current Assets
1 154
992
1 007
1 746
463
394
2 212
373
382
446
Total Current Assets
25 886
21 737
16 742
21 864
20 095
17 749
22 026
37 080
24 943
27 984
PP&E Net
2 383
4 717
8 259
11 730
13 671
8 271
3 554
3 254
3 151
3 107
PP&E Gross
0
4 717
8 259
11 730
13 671
8 271
3 554
3 254
3 151
3 107
Accumulated Depreciation
0
211
464
792
1 154
6 509
1 850
2 227
2 555
2 831
Intangible Assets
0
0
322
727
655
496
434
345
341
236
Note Receivable
2 122
2 042
2 001
3 554
3 975
3 625
3 808
4 386
3 022
2 313
Long-Term Investments
62
60
54
18
17
15
13
12
11
9
Other Long-Term Assets
1 791
1 992
2 659
1 581
701
1 177
1 311
1 255
1 798
1 917
Total Assets
32 244
N/A
30 549
-5%
30 038
-2%
39 475
+31%
39 113
-1%
31 332
-20%
31 146
-1%
46 333
+49%
33 266
-28%
35 566
+7%
Liabilities
Accounts Payable
3 080
3 277
2 789
5 059
4 058
3 571
4 661
5 705
4 278
6 254
Accrued Liabilities
573
872
889
987
1 173
1 023
1 345
1 031
947
1 142
Short-Term Debt
0
0
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
5
8
6
4
4
150
144
125
121
122
Other Current Liabilities
1 344
1 635
3 518
9 949
9 308
5 476
7 396
10 123
7 918
7 731
Total Current Liabilities
5 002
5 792
7 202
15 999
14 543
10 220
13 546
16 984
13 264
15 249
Long-Term Debt
26
16
10
6
2
269
202
76
35
65
Other Liabilities
2 775
2 908
2 758
2 897
3 170
2 638
2 616
2 643
2 555
2 476
Total Liabilities
7 803
N/A
8 716
+12%
9 970
+14%
18 902
+90%
17 715
-6%
13 126
-26%
16 364
+25%
19 703
+20%
15 853
-20%
17 790
+12%
Equity
Common Stock
847
847
847
847
1 694
1 694
1 694
1 694
1 694
1 694
Retained Earnings
23 594
20 985
19 222
19 726
19 704
16 512
13 089
24 935
15 719
16 082
Total Equity
24 441
N/A
21 832
-11%
20 069
-8%
20 573
+3%
21 398
+4%
18 206
-15%
14 783
-19%
26 630
+80%
17 413
-35%
17 776
+2%
Total Liabilities & Equity
32 244
N/A
30 549
-5%
30 038
-2%
39 475
+31%
39 113
-1%
31 332
-20%
31 146
-1%
46 333
+49%
33 266
-28%
35 566
+7%
Shares Outstanding
Common Shares Outstanding
169
169
169
169
169
169
169
169
169
169

See Also

Summary
GLAXO intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLAXO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLAXO stock valuation using valuation multiples.
Wall Street Estimates
GLAXO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLAXO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 241,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.